KRAS and rectal cancer: While Tie et al. [29] reported that ctDNA significantly outperforms standard clinicopathologic characteristics as a prognostic marker in stage II patients, Sclafani et al. [30] failed to predict the prognosis with the detection of KRAS mutation in ctDNA of locally advanced rectal cancer patients.